Dengue Fever New Vaccine
The First Vaccine For Dengue Fever Gets the "Good To Go" in 3 Countries:
The mosquito-delivered virus infects over 400 million people a year and has been no approved vaccine, until now!
When a female: Aedes Aegypti mosquito attaches to her human victim, all too often she delivers the dengue fever virus.
Worldwide the Dengue Fever virus causes as many as 400 million infections per year. The most severe cases of Dengue Fever can be excruciating painful and potentially fatal, especially among young children.
And until recently there has been no effective prevention other than avoiding the bite of Aedes Aegypti.
Dengue Fever Vaccine Breakthrough - Dengvaxia
But the fight against the disease just got stronger with the new heavy Hitter: Dengvaxia.
In December 2015 French pharmaceutical company Sanofi Pasteur, the developer of Dengvaxia, received the “green light” for use in three countries: Philippines, Mexico and Brazil, where Brazil has suffered more than 1.4 million cases of Dengue Fever in 2015 alone.
Sanofi Pasteur’s Dengvaxia, works with the body’s immune system, encouraging it into producing antibodies against all four (4) strains of the dengue virus. Dengvaxis is a vaccine consisting of an attenuated (a live organism weakened to the level that they no longer poses a disease threat, now encouraging the inducing of a protective immune response) yellow fever virus.
Dengue Fever shares the same Genus as Yellow Fever. The vaccine virus is genetically engineered to include genes encoding for Dengue proteins. According the recent Currently Dengvaxia is only approved vaccine, though other vaccines are in development.
With the massive increase in Dengue Fever reported cases Worldwide, the need for an effective vaccine is more apparent than ever.
And while Dengvaxia isn’t a perfect vaccine, it is effective in combating the disease by approximately (60) sixty percent and it has a few restrictions for administering the vaccine. Dengvaxia is only approved for the use people from the age of (9) nine through (45) forty-five who live in high risk Dengue areas.
As of April of this year the World Health Organization’s (WHO), Strategic Advisor group of Experts (SAGE) on Immunization reviewed Dengvaxia. Upon completion of the review SAGE recommended the use of the vaccine only in countries in geographic settings with an excessive endemicity.
According to Sanofi Pasteur, the Dengvaxia vaccine’s first doses have been produced and its full scale production will enable the Company to administer one-hundred (100) million doses annually.
Learn How to Treat Fevers
The Emergency First Response CPR and First Aid course provides you with valuable information in treatment for a fever.